Mostrar el registro sencillo del ítem
dc.contributor.author
García Betancur, Juan Carlos
dc.contributor.author
De La Cadena, Elsa
dc.contributor.author
Mojica, María F.
dc.contributor.author
Hernández Gómez, Cristhian
dc.contributor.author
Correa, Adriana
dc.contributor.author
Radice, Marcela Alejandra
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Castañeda Méndez, Paulo
dc.contributor.author
Jaime Villalon, Diego A.
dc.contributor.author
Gales, Ana C.
dc.contributor.author
Munita, José M.
dc.contributor.author
Villegas, María Virginia
dc.date.available
2023-11-01T13:03:17Z
dc.date.issued
2022-08
dc.identifier.citation
García Betancur, Juan Carlos; De La Cadena, Elsa; Mojica, María F.; Hernández Gómez, Cristhian; Correa, Adriana; et al.; Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 11; 8; 8-2022; 1-11
dc.identifier.issn
2079-6382
dc.identifier.uri
http://hdl.handle.net/11336/216748
dc.description.abstract
Background: Ceftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known β-lactamase inhibitor. The aim of this study was to evaluate the activity of C/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346/508) of P. aeruginosa and 83.9% (1889/2252) of Enterobacterales isolates were susceptible to C/T. Overall, C/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C/T is an active β-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
MDPI
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
ANTIMICROBIAL RESISTANCE
dc.subject
CEFTOLOZANE/TAZOBACTAM
dc.subject
ENTEROBACTERALES
dc.subject
LATIN AMERICA
dc.subject
PSEUDOMONAS AERUGINOSA
dc.subject.classification
Otras Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-11-01T12:11:21Z
dc.journal.volume
11
dc.journal.number
8
dc.journal.pagination
1-11
dc.journal.pais
Suiza
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: García Betancur, Juan Carlos. Universidad El Bosque;
dc.description.fil
Fil: De La Cadena, Elsa. Universidad El Bosque;
dc.description.fil
Fil: Mojica, María F.. Universidad El Bosque; . Case Western Reserve University; Estados Unidos
dc.description.fil
Fil: Hernández Gómez, Cristhian. Universidad El Bosque;
dc.description.fil
Fil: Correa, Adriana. Universidad Santiago de Cali; Colombia
dc.description.fil
Fil: Radice, Marcela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y BioquÍmica. Instituto de Investigaciones En Bacteriología y Virología Molecular (IBaViM); Argentina
dc.description.fil
Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México
dc.description.fil
Fil: Jaime Villalon, Diego A.. Fundacion Clinica Medica Sur; México
dc.description.fil
Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil
dc.description.fil
Fil: Munita, José M.. Universidad del Desarrollo; Chile
dc.description.fil
Fil: Villegas, María Virginia. Universidad El Bosque;
dc.journal.title
Antibiotics
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3390/antibiotics11081101
Archivos asociados